HFS
EGRX

HL Financial Services’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

HL Financial Services’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-3,854
Closed -$306K – 704
2016
Q4 		$306K Sell
3,854
-2,646
-41% -$192K 0.01% 550
2016
Q3 		$455K Hold
6,500
– – 0.01% 442
2016
Q2 		$252K Hold
6,500
– – 0.01% 573
2016
Q1 		$263K Hold
6,500
– – 0.01% 554
2015
Q4 		$576K Hold
6,500
– – 0.01% 413
2015
Q3 		$481K Sell
6,500
-1,500
-19% -$125K 0.01% 431
2015
Q2 		$647K Hold
8,000
– – 0.02% 404
2015
Q1 		$335K Buy
+8,000
New +$227K 0.01% 543

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

HL Financial Services's EGRX Position: Q1 2017 in Review

HL Financial Services sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 3,854 shares — an estimated $306K sold.

HL Financial Services first reported a position in EGRX in Q1 2015 and held it in 8 quarters. The position peaked at $647K in Q2 2015. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • HL Financial Services reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • HL Financial Services sold 3,854 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $306K.
  • HL Financial Services first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2015 and held it in 8 quarters.
  • HL Financial Services's Eagle Pharmaceuticals, Inc. position peaked at $647K in Q2 2015.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on HL Financial Services's 13F filing for Q1 2017, filed 8 May 2017.